Log In
BCIQ
Print this Print this
 

BL-5010

  Manage Alerts
Collapse Summary General Information
Company BioLineRx Ltd.
DescriptionTopical formulation of undisclosed components approved for non-surgical removal of benign skin lesions
Molecular Target
Mechanism of Action 
Therapeutic Modality 
Latest Stage of DevelopmentPhase I/II
Standard IndicationScars / wrinkles
Indication DetailsNon-surgical removal of skin lesions; Treat seborrheic keratosis
Regulatory Designation
PartnerPerrigo Co. plc

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

12/23/2014

Undisclosed

0

Undisclosed

Get a free BioCentury trial today